Apollo Hospitals Enterprise Limited (APOLLOHOSP) AI Stock Analysis

• Market Cap: ₹1.00T
• Dividend Yield: 0.27%
• Average Volume (3M): 4.82K
• Price to Earnings (P/E): 59.9
• Beta (1Y): 1.06
• Revenue Growth: 13.66%
• EPS Growth: 41.32%
• Country: IN
• Employees: 83,147
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 33.20
• Shares Outstanding: 143,784,650
• 10 Day Avg. Volume: 6,428
• 30 Day Avg. Volume: 4,819
• PEG Ratio: 1.08
• Price to Book (P/B): 11.61
• Price to Sales (P/S): 4.38
• P/FCF Ratio: 441.29
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹8,695.00
• Price Target Upside: 22.79% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 66 Neutral
• Price Target: ₹7,397.00 ▲(4.46% Upside)

Apollo Hospitals' strong financial performance is the primary driver of its stock score, supported by robust revenue growth and efficient cash flow management. However, technical indicators suggest potential bearish trends, and the high P/E ratio indicates possible overvaluation, which tempers the overall score.

Positive Factors

Revenue Growth

Sustained revenue growth (~13.7% reported) signals durable demand for Apollo’s services across hospitals, diagnostics and pharmacies. This supports capacity utilization, reinvestment in high-return services and long-term earnings expansion as the company scales its integrated care model.

Operating Cash Flow Strength

Robust operating cash generation that covers net income and positive free cash flow growth underpins financial resilience. Strong cash conversion funds growth capex, debt servicing and strategic investments without reliance on equity, supporting sustained operations and strategic flexibility.

Market Position & Integrated Network

A large, integrated network spanning tertiary hospitals, diagnostics, pharmacies and digital health provides durable competitive advantages: referral flows, cross-selling, scale economies and brand trust. This structural positioning supports steady volume growth and pricing leverage over time.

Negative Factors

Rising Capital Expenditure Pressure

Higher capex reduces free cash flow and can constrain discretionary investments or dividend flexibility if sustained. Ongoing heavy investments require clear return paths; otherwise they may compress margins or force additional financing, weakening long-term cash returns to shareholders.

Leverage Management Needed

While current leverage appears manageable, the company must actively control debt as it expands. Increased borrowing for expansions or acquisitions would reduce financial flexibility, raise interest burdens and heighten vulnerability to demand shocks in a capital‑intensive healthcare business.

Revenue Concentration in Hospital Operations

Heavy reliance on hospital services concentrates revenue and exposes performance to utilization cycles, regulatory reimbursement shifts and capital intensity. Limited structural diversification increases sensitivity to sector-specific headwinds versus firms with broader payor or geographic revenue mixes.

Apollo Hospitals Enterprise Limited Business Overview & Revenue Model

Company Description

Apollo Hospitals Enterprise Limited, together with its subsidiaries, provides healthcare services in India and internationally. The company's healthcare facilities comprise primary, secondary, and tertiary care facilities. Its tertiary care hospitals provide advanced healthcare services; and specialties in cardiac sciences, oncology, neurosciences, orthopedics, emergency, robotic surgery, and transplants. The company also provides other services, such as project consultancy, health insurance, medical colleges, medvarsity for e-learning, and research services. In addition, it operates pharmacies, primary care clinics, birthing centers, specialized birthing centers, single specialty clinics, primary health centers and diagnostic chains, dental clinics, and daycare and home healthcare centers. The company's footprint includes 9,911 beds, 4,529 pharmacies, and 1,734 national retail healthcare centers, as well as Apollo 24/7, an end-to-end omni-channel healthcare platform and www.apollopharmacy, an online pharmacy. Apollo Hospitals Enterprise Limited was incorporated in 1979 and is based in Chennai, India.

How the Company Makes Money

Apollo Hospitals generates revenue primarily through its hospital operations, which include inpatient and outpatient services. The company charges fees for various medical services, surgeries, and treatments provided in its hospitals. Additionally, Apollo earns significant income from its diagnostic services, including laboratory tests and imaging services. The retail pharmacy segment contributes to revenue by selling prescription and over-the-counter medications, health products, and wellness services. Strategic partnerships with insurance companies and health plans also enhance revenue through reimbursements for services rendered. Furthermore, Apollo has ventured into digital health initiatives, which provide an additional revenue stream through telemedicine and online consultations.

Apollo Hospitals Enterprise Limited Financial Statement Overview

Summary

Apollo Hospitals demonstrates strong financial performance with robust revenue growth, improved profitability, and efficient cash flow management. The balance sheet is stable, though maintaining control over debt levels is important for future stability.

Income Statement

Apollo Hospitals shows strong revenue growth with a significant increase in total revenue over the past year. The gross profit margin is healthy, indicating efficient cost management. The net profit margin has improved, demonstrating increased profitability. Both EBIT and EBITDA margins are robust, reflecting effective operations and earnings before interest, taxes, depreciation, and amortization.

Balance Sheet

The company's balance sheet reflects a stable financial position with a reasonable debt-to-equity ratio, suggesting manageable leverage. The equity ratio indicates a strong capital structure. The return on equity shows good profitability from shareholders' investments, though there is room for improvement.

Cash Flow

Apollo Hospitals maintains strong operating cash flow, which covers net income well, indicating efficient cash conversion. The free cash flow growth rate is commendable, although the capital expenditures have increased, impacting free cash flow. The company shows effective cash management to support operations and future investments.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	225.50B	217.94B	190.59B	166.13B	146.63B	105.60B
Gross Profit	76.27B	73.50B	63.98B	56.68B	51.31B	31.40B
EBITDA	29.83B	27.98B	22.11B	19.11B	20.45B	9.75B
Net Income	15.90B	14.46B	8.99B	8.19B	10.56B	1.50B
Balance Sheet
Total Assets	0.00	206.57B	167.53B	144.28B	131.92B	114.17B
Cash, Cash Equivalents and Short-Term Investments	20.10B	27.93B	11.89B	7.26B	10.48B	14.23B
Total Debt	0.00	78.64B	53.33B	43.32B	40.68B	41.60B
Total Liabilities	-86.53B	120.05B	94.33B	78.96B	73.15B	66.14B
Stockholders Equity	86.53B	82.12B	69.35B	61.97B	56.23B	46.02B
Cash Flow
Free Cash Flow	0.00	2.16B	7.83B	2.49B	9.71B	9.78B
Operating Cash Flow	0.00	19.29B	19.20B	13.77B	16.28B	12.73B
Investing Cash Flow	0.00	-34.77B	-15.37B	-8.71B	-8.47B	-8.72B
Financing Cash Flow	0.00	16.21B	-3.11B	-6.33B	-7.93B	-3.40B

Apollo Hospitals Enterprise Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7081.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:APOLLOHOSP, the sentiment is Negative. The current price of 7081.4 is above the 20-day moving average (MA) of 7076.07, below the 50-day MA of 7117.25, and below the 200-day MA of 7322.88, indicating a bearish trend. The MACD of -97.30 indicates Positive momentum. The RSI at 45.59 is Neutral, neither overbought nor oversold. The STOCH value of 37.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:APOLLOHOSP.

Apollo Hospitals Enterprise Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NH	71 Outperform	₹361.28B	42.54	―	0.24%	14.72%	8.37%
APOLLOHOSP	66 Neutral	₹1.00T	59.86	―	0.27%	13.66%	41.32%
MAXHEALTH	66 Neutral	₹931.21B	68.56	―	0.14%	32.17%	28.12%
MEDANTA	65 Neutral	₹283.59B	50.46	―	0.04%	15.78%	15.01%
FORTIS	61 Neutral	₹642.96B	63.41	―	0.11%	15.33%	54.62%
METROPOLIS	61 Neutral	₹97.21B	61.27	―	0.21%	15.41%	5.93%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Apollo Hospitals Enterprise Limited Corporate Events

Apollo Hospitals Confirms SEBI-Compliant Dematerialisation of Shares for December 2025 Quarter

Apollo Hospitals Enterprise Limited has reported that, for the quarter ended 31 December 2025, all equity share certificates submitted for dematerialisation were duly processed, verified, and either accepted or rejected and communicated to the depositories and stock exchanges where its shares are listed. The registrar confirmed that physical security certificates received for dematerialisation were mutilated and cancelled after verification, with the depositories’ names recorded as registered owners within the stipulated regulatory timelines, underscoring the company’s compliance with SEBI’s Regulation 74(5) on depositories and participants and supporting orderly trading and settlement in its shares.